• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 7, 2020
Company Drug/Device Medical Condition Status
Asklepios BioPharmaceutical NAN-101 congestive heart failure phase 1 trial dosing first patient
Immix Biopharma Imx-110 advanced solid tumors phase 1b/2a trial dosing first patient in U.S.
Moleculin Biotech Liposomal Annamycin (annamycin) relapsed or refractory acute myeloid leukemia phase 1 trial completed
AIVITA Biomedical AV-GBM-1 glioblastoma phase 2 trial enrollment completed
Alkahest AKST4290 Parkinson’s Disease phase 2 trial dosing first patient
Minerva Neurosciences roluperidone schizophrenia phase 3 trial enrolling 515 patients in the U.S. and Europe
INVO Bioscience INVOcell infertility phase 3 trial enrolling 180 patients at three sites in the U.S.
VistaGen Therapeutics AV-101 dyskinesia in Parkinson's Disease patients phase 2 IND awarded by the FDA
GlycoMimetics GMI-1359 osteosarcoma Orphan Drug and Rare Pediatric Disease designations granted by the FDA
Aria CV Aria CV Pulmonary Hypertension System pulmonary arterial hypertension Breakthrough Device designation awarded by the FDA
ReAlta Life Sciences PIC1-dPEG24 hypoxic-ischemic encephalopathy in neonates Orphan Drug designation awarded by the FDA
EyeYon Medical EndoArt film implant chronic corneal edema secondary to endothelial dysfunction Breakthrough Device designation awarded by the FDA
VIVUS PANCREAZE (pancrelipase) Delayed Release Capsules exocrine pancreatic insufficiency due to cystic fibrosis or other conditions supplemental NDA approved by the FDA
Seqirus Audenz vaccine potential pandemic associated with the H5N1 flu virus approved by the FDA
Aimmune Therapeutics Palforzia (AR101) pediatric patients, ages 4 to 17, who have an allergy to peanuts approved by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing